Welcome to our dedicated page for Savara SEC filings (Ticker: SVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Savara Inc. (SVRA) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases, and its filings offer detailed insight into the development and financing of its lead program, MOLBREEVI, for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).
Through this page, readers can review current and historical reports such as Forms 8-K, which describe material events including public offerings of common stock and pre-funded warrants, royalty funding agreements tied to potential future U.S. net sales of MOLBREEVI, and updates to corporate presentations. Filings also confirm that Savara’s common stock trades on The Nasdaq Global Select Market under the symbol SVRA and describe the company’s status as a clinical stage biopharmaceutical company focused on rare respiratory diseases.
Key documents for investors include periodic reports like annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain information on research and development expenses, general and administrative costs, and other financial data related to the MOLBREEVI program and corporate operations. Current reports on Form 8-K highlight transactions such as underwritten public offerings, the entry into material definitive agreements, and royalty funding arrangements.
Stock Titan enhances these filings with AI-powered summaries that help explain the significance of complex disclosures, including capital-raising transactions, royalty structures, and covenants described in agreements. Users can quickly understand how specific filings relate to Savara’s rare respiratory disease focus, its Phase 3 development of MOLBREEVI, and its preparation for potential commercialization, while still having direct access to the full text of each SEC document.
BlackRock, Inc. has disclosed a significant ownership stake in Savara Inc. common stock on a Schedule 13G. BlackRock reports beneficial ownership of 10,957,322 shares of Savara common stock, representing 5.4% of the outstanding class as of the event date 12/31/2025. BlackRock has sole voting power over 10,820,963 shares and sole dispositive power over 10,957,322 shares, with no shared voting or dispositive power.
The filing states that these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Savara. Various underlying clients and investors have the right to receive dividends or sale proceeds, but no single person has more than five percent of the total outstanding common shares.
Savara Inc. has furnished an updated corporate presentation for investors. The presentation is available on the company’s Investor Relations website and has also been provided as Exhibit 99.1 to a current report. Savara states it has no duty to update or revise the presentation, although it may choose to do so through its website, future SEC reports, press releases, or other public disclosures. The information in this investor presentation is expressly treated as furnished rather than filed under securities laws and is not automatically incorporated into other SEC filings unless specifically referenced.
Savara Inc's Chief Financial Officer, David Lowrance, reported two transactions in the company’s common stock. On December 14, 2025, 62,960 shares were disposed of at $6.92 per share, representing shares withheld by Savara to cover tax liabilities from the vesting of previously awarded restricted stock units, leaving him with 318,045 shares owned directly.
On December 16, 2025, he reported a bona fide gift of 32,000 shares to The McCallie School at a reported price of $0.00 per share, after which he directly owned 286,045 shares of Savara common stock. He does not have voting or investment power over the shares held by The McCallie School.
Savara Inc director and chief executive officer Matthew Pauls reported two changes in his common stock holdings. On 12/14/2025, 195,705 shares of common stock were disposed of at $6.92 per share, representing shares withheld by the company to cover tax liabilities arising from the vesting of previously awarded restricted stock units. After this, he held 1,317,045 shares.
On 12/16/2025, he reported a disposition of 128,995 common shares at a price of $0.00, reflecting a transfer to the GP 2024 Trust, U/A dated 12/20/2024, for no consideration. He is not a trustee of the trust and does not retain investment or voting control over those shares, and disclaims beneficial ownership except to the extent of any pecuniary interest. Following this gift, he beneficially owns 1,188,050 Savara common shares directly.
Savara Inc reported an insider equity transaction by its Chief Operating Officer, Robert Lutz. On 12/14/2025, the company withheld 67,760 shares of Savara common stock at $6.92 per share to cover his tax obligations arising from the vesting of previously awarded restricted stock units.
After this tax-related share withholding, Robert Lutz directly beneficially owned 293,977 shares of Savara common stock.
Savara Inc's chief legal officer reported an equity transaction involving company stock. On 12/14/2025, Savara withheld 39,350 shares of common stock at $6.92 per share to satisfy the reporting person's tax liability arising from the vesting of previously awarded restricted stock units. After this tax withholding transaction, the officer beneficially owned 519,232 shares of Savara common stock directly.
Savara Inc chief business officer Anne Erickson reported a tax-related disposition of common stock. On 12/14/2025, 62,960 shares of Savara common stock were withheld by the company at a price of $6.92 per share to satisfy her tax liability upon vesting of previously awarded restricted stock units. After this withholding transaction, she directly beneficially owns 371,712 Savara shares.
Savara Inc. director Richard Hawkins reported an equity award of 40,000 restricted stock units (RSUs) of Savara common stock dated December 9, 2025. The RSUs vest in full on December 9, 2026, provided he continues his service with the company, and each RSU represents a right to receive one share of common stock. He has elected to defer delivery of the vested shares until after his service with Savara ends. Following this grant, he beneficially owns 161,326 shares of Savara common stock in direct ownership.
Savara Inc director David Ramsay reported the acquisition of 40,000 restricted stock units (RSUs) tied to the company’s common stock on December 9, 2025. The RSUs vest in full on December 9, 2026, provided he continues to serve with Savara, and each RSU represents a contingent right to receive one share of common stock. The transaction price was listed as $0.00, indicating no cash was paid for the award. Following this grant, Ramsay beneficially owns 2,553,642 shares of Savara common stock in direct ownership.
Savara Inc director Joseph S. McCracken reported acquiring 40,000 shares of common stock on December 9, 2025 at a reported price of $0.00 per share. Following this equity award, he beneficially owns 300,837 shares of Savara common stock directly.
The 40,000 shares are described as restricted stock units (RSUs) that vest in full on December 9, 2026, if he continues his service with the company. Each RSU represents a contingent right to receive one share of common stock, and he has elected to defer receipt of these shares so that they will be delivered after his service with Savara ends.
FAQ
What is the current stock price of Savara (SVRA)?
What is the market cap of Savara (SVRA)?
